Market Cap 136.28M
Revenue (ttm) 0.00
Net Income (ttm) -12.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 191,900
Avg Vol 186,160
Day's Range N/A - N/A
Shares Out 32.92M
Stochastic %K 53%
Beta 0.69
Analysts Strong Sell
Price Target $9.00

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 708 9808
Address:
3150 Almaden Expressway, Suite 250, San Jose, United States
loginname
loginname Oct. 28 at 4:28 AM
$ANIX there are many bid at 4 the price can’t easy down from 4 i am waiting for 3.8 but that never come next week, $ANIX will have Spartan capital sccurities if you want to bet just in this week, if you want to invest waiting 2-4 days after Spartan.
0 · Reply
loginname
loginname Oct. 24 at 3:33 PM
$ANIX good boy, mama has warmed you a cup of milk
2 · Reply
loginname
loginname Oct. 23 at 7:36 PM
$ANIX this fri or next week 🚀 too long sideway. it’s time!!
0 · Reply
topstockalerts
topstockalerts Oct. 20 at 3:34 PM
Anixa Biosciences shares rose 2.2% in premarket trading Monday after the company announced it received a Chinese patent for its breast cancer vaccine technology. The National Intellectual Property Administration of China issued Patent No. ZL2020800215666, covering key aspects of Anixa’s breast cancer vaccine and extending protection into the 2040s across multiple global jurisdictions. Developed in collaboration with Cleveland Clinic, the vaccine targets human α-lactalbumin, a lactation-associated protein abnormally expressed in certain breast cancers. The approach aims to train the immune system to prevent tumor formation without harming normal tissue. “This newly issued patent further validates the novelty and potential of our breast cancer vaccine,” said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. He added that the patent strengthens the company’s ability to pursue global strategic opportunities as it advances clinical development in the U.S. $ANIX
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 20 at 12:27 PM
$ANIX (+9.8% pre) Anixa Biosciences (ANIX) Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology https://ooc.bz/l/81164
0 · Reply
LisaBethK
LisaBethK Oct. 19 at 8:57 PM
$BCG Saw this posted on X earlier. Really exciting. Not planning on fomo but will be adding at reasonable levels in PM if I get the chance. Also adding $ANIX to WL for news cycle setup.
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 17 at 12:00 AM
0 · Reply
research_WTR
research_WTR Oct. 16 at 5:20 PM
Read Robert Sassoon's recap from his latest podcast with Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: $ANIX) Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=IR_Healt_10122025 $ANIX #Healthcare #Nutrigenomics #Podcast #SmallCap #Stocks #Investing #LoveBiome
0 · Reply
stockobserver51
stockobserver51 Oct. 16 at 5:11 PM
$ANIX If the Nasdaq falls by a quarter soon, December 11 will be nothing more than a consolation prize for the stock.
0 · Reply
bobgilbert
bobgilbert Oct. 16 at 3:50 AM
$ANIX with this vaccine this company goes ballistic. 👍
0 · Reply
Latest News on ANIX
Anixa Biosciences: Oncology Platform With Asymmetric Upside

Jul 15, 2025, 3:49 PM EDT - 3 months ago

Anixa Biosciences: Oncology Platform With Asymmetric Upside


Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Jun 20, 2025, 7:30 AM EDT - 4 months ago

Anixa Biosciences to Host an Investor Webcast on June 26, 2025


Anixa Biosciences CEO Provides Letter to Shareholders

Jan 21, 2025, 8:30 AM EST - 9 months ago

Anixa Biosciences CEO Provides Letter to Shareholders


loginname
loginname Oct. 28 at 4:28 AM
$ANIX there are many bid at 4 the price can’t easy down from 4 i am waiting for 3.8 but that never come next week, $ANIX will have Spartan capital sccurities if you want to bet just in this week, if you want to invest waiting 2-4 days after Spartan.
0 · Reply
loginname
loginname Oct. 24 at 3:33 PM
$ANIX good boy, mama has warmed you a cup of milk
2 · Reply
loginname
loginname Oct. 23 at 7:36 PM
$ANIX this fri or next week 🚀 too long sideway. it’s time!!
0 · Reply
topstockalerts
topstockalerts Oct. 20 at 3:34 PM
Anixa Biosciences shares rose 2.2% in premarket trading Monday after the company announced it received a Chinese patent for its breast cancer vaccine technology. The National Intellectual Property Administration of China issued Patent No. ZL2020800215666, covering key aspects of Anixa’s breast cancer vaccine and extending protection into the 2040s across multiple global jurisdictions. Developed in collaboration with Cleveland Clinic, the vaccine targets human α-lactalbumin, a lactation-associated protein abnormally expressed in certain breast cancers. The approach aims to train the immune system to prevent tumor formation without harming normal tissue. “This newly issued patent further validates the novelty and potential of our breast cancer vaccine,” said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. He added that the patent strengthens the company’s ability to pursue global strategic opportunities as it advances clinical development in the U.S. $ANIX
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 20 at 12:27 PM
$ANIX (+9.8% pre) Anixa Biosciences (ANIX) Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology https://ooc.bz/l/81164
0 · Reply
LisaBethK
LisaBethK Oct. 19 at 8:57 PM
$BCG Saw this posted on X earlier. Really exciting. Not planning on fomo but will be adding at reasonable levels in PM if I get the chance. Also adding $ANIX to WL for news cycle setup.
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 17 at 12:00 AM
0 · Reply
research_WTR
research_WTR Oct. 16 at 5:20 PM
Read Robert Sassoon's recap from his latest podcast with Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: $ANIX) Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=IR_Healt_10122025 $ANIX #Healthcare #Nutrigenomics #Podcast #SmallCap #Stocks #Investing #LoveBiome
0 · Reply
stockobserver51
stockobserver51 Oct. 16 at 5:11 PM
$ANIX If the Nasdaq falls by a quarter soon, December 11 will be nothing more than a consolation prize for the stock.
0 · Reply
bobgilbert
bobgilbert Oct. 16 at 3:50 AM
$ANIX with this vaccine this company goes ballistic. 👍
0 · Reply
Kher33
Kher33 Oct. 15 at 11:53 PM
$ANIX https://www.kjrh.com/health/promising-breast-cancer-vaccine-could-be-available-by-2030-researchers-say?fbclid=IwZnRzaANdEzxleHRuA2FlbQIxMQABHlqhOAvCRSdsj5gVhHd9KGt4LMk3y5937LtQQRZSBSjGdbJ0UsKCrdp5AS_3_aem_-Q-M4g-J_2bamsZh5F9xyA
0 · Reply
JMAR_WTR
JMAR_WTR Oct. 15 at 6:29 PM
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 15 at 6:17 PM
0 · Reply
research_WTR
research_WTR Oct. 15 at 4:52 PM
New Episode: WTR Healthcare Happenings with Amit Kumar CEO of Anixa Biosciences (NASDAQ: $ANIX) 🔹 Discusses t-cell innovation and two groundbreaking clinical programs: 🔹 Modified CAR-T therapy designed to overcome challenges in treating solid tumors, including ovarian cancer 🔹 A breast cancer vaccine training antigen-specific t-cells to target triple-negative breast cancer — the most aggressive form 🔹 Hear insights on Anixa’s financial strength and strategy to drive these programs toward commercialization 🎧 Listen now on Apple Podcasts, Spotify, or at our website! Apple: https://podcasts.apple.com/us/podcast/ceo-dr-amit-kumar-discusses-anixa-biosciences-innovative/id1795488592?i=1000731955891 Spotify: https://open.spotify.com/episode/2hEd8syJqnZzNBMfh9vdWs?si=c3cdaf92c2374d67 Website: https://www.watertowerresearch.com/media-detail/2652/Media Others: https://pod.link/1795488592 #AnixaBiosciences $ANIX #Biotech #CancerResearch #CAR_T #Immunotherapy #BreastCancer #OvarianCancer #HealthcareInvesting #SmallCapStocks #WaterTowerResearch
0 · Reply
ChessHere
ChessHere Oct. 15 at 1:08 PM
$ANIX $ANIX wow! a lot of movement on p1 trial finished - no new news, no new data, no new insider buying… in other words there is nothing to justify the sp increase other than emotional reaction spurred by wanting Anixa to be successful ( me included). But expect the sp to go back to low 3’s until we get close to data release in Dec.. Just like every Oct. for the past three years.
0 · Reply
ChessHere
ChessHere Oct. 15 at 1:02 PM
0 · Reply
justiceforb_85
justiceforb_85 Oct. 10 at 7:53 PM
$ANIX long here and adding. Data in December will tell whether targeting alpha-lactalbumin translates from pre-clinical work in mice to humans. Would be a stunning breakthrough.
0 · Reply
Searchingforthecure
Searchingforthecure Oct. 10 at 6:01 PM
$ANIX Amit should make the largest buy of his tenure. Followed by every board member and employee. That would be a huge sign of good results to come. They also need a huge partnership. I hope they can announce a $100M+ commercial partnership rather than do any dilution. Or he could sell one of the technologies and that would be a major win and allow them to do more early stage work!
0 · Reply
Rideabull
Rideabull Oct. 10 at 4:59 PM
$ANIX Typical slow Friday before a holiday..will pick up next week.
0 · Reply
Drugtrade
Drugtrade Oct. 10 at 3:30 PM
$ANIX im long here.. added
0 · Reply
TDMF123
TDMF123 Oct. 10 at 2:07 PM
$ANIX Position Taken
0 · Reply
bioinvestorrr
bioinvestorrr Oct. 10 at 12:37 PM
$ANIX at this rate idk when she will slow down, huge anticipation for december seems like everyone wants in
1 · Reply